Cargando…
Azithromycin, a questionable treatment for COVID-19
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817454/ https://www.ncbi.nlm.nih.gov/pubmed/33476733 http://dx.doi.org/10.1016/j.ijantimicag.2021.106280 |
| _version_ | 1783638642564005888 |
|---|---|
| author | Belfaqeeh, O. Janapala, R.N. Patel, J. Alhashmi, A. Pourmand, A. |
| author_facet | Belfaqeeh, O. Janapala, R.N. Patel, J. Alhashmi, A. Pourmand, A. |
| author_sort | Belfaqeeh, O. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7817454 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd and International Society of Antimicrobial Chemotherapy. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78174542021-01-21 Azithromycin, a questionable treatment for COVID-19 Belfaqeeh, O. Janapala, R.N. Patel, J. Alhashmi, A. Pourmand, A. Int J Antimicrob Agents Letter to the Editor Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021-03 2021-01-19 /pmc/articles/PMC7817454/ /pubmed/33476733 http://dx.doi.org/10.1016/j.ijantimicag.2021.106280 Text en © 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Belfaqeeh, O. Janapala, R.N. Patel, J. Alhashmi, A. Pourmand, A. Azithromycin, a questionable treatment for COVID-19 |
| title | Azithromycin, a questionable treatment for COVID-19 |
| title_full | Azithromycin, a questionable treatment for COVID-19 |
| title_fullStr | Azithromycin, a questionable treatment for COVID-19 |
| title_full_unstemmed | Azithromycin, a questionable treatment for COVID-19 |
| title_short | Azithromycin, a questionable treatment for COVID-19 |
| title_sort | azithromycin, a questionable treatment for covid-19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817454/ https://www.ncbi.nlm.nih.gov/pubmed/33476733 http://dx.doi.org/10.1016/j.ijantimicag.2021.106280 |
| work_keys_str_mv | AT belfaqeeho azithromycinaquestionabletreatmentforcovid19 AT janapalarn azithromycinaquestionabletreatmentforcovid19 AT patelj azithromycinaquestionabletreatmentforcovid19 AT alhashmia azithromycinaquestionabletreatmentforcovid19 AT pourmanda azithromycinaquestionabletreatmentforcovid19 |